Lascco
Company Team Projects Media Contact
    
   


MANAGEMENT

Samareh Lajaunias

Samareh Lajaunias Azeredo da Silveira - Managing Director
Samareh is an early-stage drug development specialist. In 2007, she co-founded LASCCO SA, a virtual incubator dedicated to the identification of discovery-stage pharmaceuticals and diagnostics. Since then, she focused on the development of breakthrough technolgies in the fields of critical care and infectious diseases. From 2011 to 2018, she was a partner at Sepstone Diagnostics, a spin-off of LASCCO, where she outlicensed a sepsis diagnostic technology to several industural partners. Samareh holds a PhD in Neurosciences from Ecole Polytechnique Fédérale de Lausanne (EPFL) – lab of Prof. Patrick Aebischer. She authored numerous publications and opinion reviews.

Frederic Lajaunias

Frédéric Lajaunias - Managing Director
Frédéric has 9 year experience in early stage development. In 2007, he co-founded LASCCO SA, a biomedical technology development company focusing on discovery-stage pharmaceuticals and diagnostics. Prior to founding LASCCO, Frédéric served at Abbott Laboratories as manager for the Swiss virology division. Before that, he carried out a post-doctoral work at the Geneva University Hospital studying autoimmune disorders.Frédéric holds a PhD in biology (immunology), from the University of Paris VII, andan MBA with a specialization in Entrepreneurship from the University of Geneva.

Toni Perez

Toni Perez - Chief Medical Officer
Toni is a MD, specialist in Intensive Care, with diplomas of Pharmaceutical Industry and General Management Program. Prior to joining Combioxin, Toni was Head of Clinical Research of Infectious Diseases at Novartis, Head of Clinical Development of Anti-Infectives at Basilea Pharmaceutica, Area Head of Clinical Research in Oncology at Almirall, Medical Director of Gastro-intestinal track and CNS and a board member at Esteve. He is a consultant to several pharma companies. During is career, Toni has contributed to the development, registration and marketing of medicines in infectious diseases, oncology, CNS, and gastro-intestinal and urinary tracts among others.

Shelly Bustion

Shelly Bustion - Head of Clinical Operations
Shelly is a multinational expert in clinical trial/program and line manager with over 19 years of experience in the pharmaceutical and medical device industries. She has conducted several clinical trials in all development phases and in many therapeutic areas. Shelly has managed team members at strategic program and clinical trial levels. She has in-depth knowledge of the various clinical development areas and has brought 6 products to the market. Shelly is also a lecturer and trainer at the University of Geneva.

Kristen Peterson

Kristen Peterson - Pharmaceutical Development and CMC
Kristen is a pharmaceuticals expert with over 20 years of experience in process and product development of liposomes. She has directed the process development, scale-up and technology transfer of numerous products from early clinical development through commercialization. Kristen held director-level positions in liposomal process development and manufacturing at ALZA. She also held various Engineering positions with Sequus Pharmaceuticals where she was instrumental in the Doxil® manufacturing process development. Prior to Sequus, she worked at Syntex on other sterile controlled release dosage forms. Kristen received her B.S. in Chemical Engineering from the University of California, Berkeley.